Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Above 50-Day Moving Average – What’s Next?

Theravance Biopharma, Inc. (NASDAQ:TBPH) shares crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $9.30 and traded as high as $9.44. Theravance Biopharma shares last traded at $9.35, with a volume of 167,372 shares trading hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a report on Tuesday, February 25th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Theravance Biopharma has an average rating of “Hold” and a consensus target price of $13.75.

Theravance Biopharma Trading Up 1.3 %

The stock has a market capitalization of $462.55 million, a P/E ratio of -9.26 and a beta of 0.15. The company’s 50-day moving average is $9.30 and its two-hundred day moving average is $9.03.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The company had revenue of $18.75 million during the quarter, compared to analyst estimates of $29.90 million. Sell-side analysts expect that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at $2,786,085. The trade was a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 6.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several large investors have recently bought and sold shares of the stock. Barclays PLC increased its position in shares of Theravance Biopharma by 279.9% during the 3rd quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock worth $529,000 after purchasing an additional 48,316 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Theravance Biopharma by 2.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 266,879 shares of the biopharmaceutical company’s stock worth $2,151,000 after purchasing an additional 7,620 shares in the last quarter. Algert Global LLC acquired a new stake in shares of Theravance Biopharma during the 3rd quarter worth about $851,000. Jane Street Group LLC increased its position in shares of Theravance Biopharma by 1.1% during the 3rd quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock worth $1,165,000 after purchasing an additional 1,640 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of Theravance Biopharma by 88.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock worth $2,462,000 after purchasing an additional 143,781 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.